A promising breakthrough in cancer cachexia treatment

Cancer cachexia is a common and severe cancer complication characterized by significant weight and muscle loss, often associated with increased morbidity and mortality. Recent research highlights the central role of growth differentiation factor 15 (GDF-15) in its pathophysiology. Ponsegromab, a humanized monoclonal antibody targeting and inhibiting GDF-15, has shown promising effects, including increased body weight, improved appetite and physical activity, and reduced serum GDF-15 levels. This study evaluates the efficacy and safety of ponsegromab in treating cancer cachexia.